X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AUROBINDO PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AUROBINDO PHARMA GLENMARK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 14.2 15.6 91.1% View Chart
P/BV x 3.8 4.0 93.7% View Chart
Dividend Yield % 0.3 0.4 82.5%  

Financials

 GLENMARK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
AUROBINDO PHARMA
Mar-17
GLENMARK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs993895 110.9%   
Low Rs729622 117.3%   
Sales per share (Unadj.) Rs325.5254.6 127.9%  
Earnings per share (Unadj.) Rs39.339.3 100.0%  
Cash flow per share (Unadj.) Rs48.746.6 104.5%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.20.3 70.5%  
Book value per share (Unadj.) Rs159.2160.0 99.5%  
Shares outstanding (eoy) m282.17585.88 48.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.63.0 88.8%   
Avg P/E ratio x21.919.3 113.5%  
P/CF ratio (eoy) x17.716.3 108.7%  
Price / Book Value ratio x5.44.7 114.1%  
Dividend payout %5.16.4 80.0%   
Avg Mkt Cap Rs m242,991444,390 54.7%   
No. of employees `00013.014.0 92.7%   
Total wages/salary Rs m16,40817,678 92.8%   
Avg. sales/employee Rs Th7,083.910,667.8 66.4%   
Avg. wages/employee Rs Th1,265.41,264.3 100.1%   
Avg. net profit/employee Rs Th855.11,645.8 52.0%   
INCOME DATA
Net Sales Rs m91,857149,157 61.6%  
Other income Rs m3741,159 32.2%   
Total revenues Rs m92,230150,316 61.4%   
Gross profit Rs m20,36734,343 59.3%  
Depreciation Rs m2,6444,276 61.8%   
Interest Rs m2,373667 355.7%   
Profit before tax Rs m15,72430,558 51.5%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8277,597 50.4%   
Profit after tax Rs m11,08823,012 48.2%  
Gross profit margin %22.223.0 96.3%  
Effective tax rate %24.324.9 97.9%   
Net profit margin %12.115.4 78.2%  
BALANCE SHEET DATA
Current assets Rs m68,74692,062 74.7%   
Current liabilities Rs m27,02766,223 40.8%   
Net working cap to sales %45.417.3 262.2%  
Current ratio x2.51.4 183.0%  
Inventory Days Days85106 80.2%  
Debtors Days Days9668 141.2%  
Net fixed assets Rs m24,13262,919 38.4%   
Share capital Rs m282586 48.2%   
"Free" reserves Rs m44,64393,133 47.9%   
Net worth Rs m44,92593,719 47.9%   
Long term debt Rs m45,3631,814 2,500.7%   
Total assets Rs m117,639162,494 72.4%  
Interest coverage x7.646.8 16.3%   
Debt to equity ratio x1.00 5,216.8%  
Sales to assets ratio x0.80.9 85.1%   
Return on assets %11.414.6 78.5%  
Return on equity %24.724.6 100.5%  
Return on capital %19.132.7 58.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15275,838 74.0%   
Fx outflow Rs m8,08430,224 26.7%   
Net fx Rs m48,06845,613 105.4%   
CASH FLOW
From Operations Rs m6,57432,786 20.1%  
From Investments Rs m-7,124-17,870 39.9%  
From Financial Activity Rs m5,432-19,153 -28.4%  
Net Cashflow Rs m1,992-4,239 -47.0%  

Share Holding

Indian Promoters % 48.3 54.1 89.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.0 86.8%  
FIIs % 34.4 27.7 124.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.2 102.9%  
Shareholders   56,727 69,601 81.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - TORRENT PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS